Bicycle Therapeutics plc
BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5ā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.37
Price+3.07%
$0.13
1Y
Price
Market Cap
$303.254m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-7811.1%
EBITDA Margin-8002.1%
Net Profit Margin-7928.6%
Free Cash Flow Margin-7811.1%
EBITDA Margin-8002.1%
Net Profit Margin-7928.6%
Free Cash Flow MarginRevenue
$61.205m
-15.7%
1y CAGR+40.3%
3y CAGR+51.8%
5y CAGREarnings
-$190.412m
+13.0%
1y CAGR-3.3%
3y CAGR-17.6%
5y CAGREPS
-$2.73
+13.6%
1y CAGR+15.9%
3y CAGR+3.5%
5y CAGRBook Value
$510.255m
$606.578m
Assets$96.323m
Liabilities$13.680m
DebtDebt to Assets
2.3%
-0.1x
Debt to EBITDAFree Cash Flow
-$205.592m
+18.6%
1y CAGR-64.9%
3y CAGR-38.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company